Browsing Tag
cardiovascular prevention
2 posts
Amgen’s landmark Repatha trial to take center stage at AHA 2025 with major cardiovascular prevention results
Find out how Amgen’s Repatha phase 3 trial is redefining cardiovascular prevention and reshaping investor sentiment at AHA 2025.
October 31, 2025
FDA approves Amgen’s Repatha for heart attack and stroke prevention
In a significant advancement for cardiovascular disease management, Amgen’s Repatha (evolocumab) has received approval from the U.S. Food…
December 9, 2017